A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
NCT: NCT03530852 · RECRUITING
Brief Summary
Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition
Frequently Asked Questions
What is A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB?
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB is a clinical trial registered under NCT03530852. Current status: RECRUITING.
What is the status of NCT03530852?
The current status of NCT03530852 (A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB) is: RECRUITING.
When did A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB start?
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB started on 2018-11-21.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.